Meta-analysis of genome-wide association studies of HDL cholesterol response to statins.Protein-altering and regulatory genetic variants near GATA4 implicated in bicuspid aortic valve.Diagnosis, Prevalence, Awareness, Treatment, Prevention, and Control of Hypertension in Cameroon: Protocol for a Systematic Review and Meta-Analysis of Clinic-Based and Community-Based StudiesPharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins.Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib.Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation: Concordance With Clinical OutcomesComparison of genotype clustering tools with rare variantsImpact of regular physical activity on weekly warfarin dose requirement.Beneficial Effects of Reconstituted High-Density Lipoprotein (rHDL) on Circulating CD34+ Cells in Patients after an Acute Coronary Syndrome.Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry.Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease.Resting heart rate in cardiovascular disease.Calcium Signaling Pathway Genes RUNX2 and CACNA1C Are Associated With Calcific Aortic Valve DiseasePillbox Use and INR Stability in a Prospective Cohort of New Warfarin Users.Older adults with heart failure treated with carvedilol, bisoprolol, or metoprolol tartrate: risk of mortality.A model to assess the cost-effectiveness of pharmacogenomics tests in chronic heart failure: the case of ivabradine.Maximal expected benefits from lowering cholesterol in primary prevention for a high-risk population.Validation of patient-reported warfarin dose in a prospective incident cohort study.Evaluation of links between high-density lipoprotein genetics, functionality, and aortic valve stenosis risk in humans.Polygenic determinants in extremes of high-density lipoprotein cholesterol.Pharmacogenetics of Lipid-Lowering Agents: an Update Review on Genotype-Dependent Effects of HDL-Targetingand Statin Therapies.Validation of warfarin pharmacogenetic algorithms in clinical practice.CETP: Pharmacogenomics-Based Response to the CETP Inhibitor Dalcetrapib.Polygenic Versus Monogenic Causes of Hypercholesterolemia Ascertained Clinically.A Discrete Event Simulation Model to Assess the Economic Value of a Hypothetical Pharmacogenomics Test for Statin-Induced Myopathy in Patients Initiating a Statin in Secondary Cardiovascular Prevention.Precision medicine to change the landscape of cardiovascular drug developmentInvestigational drugs in development for hypertriglyceridemia: a coming-of-age storyOral Anticoagulant Prescription Trends, Profile Use, and Determinants of Adherence in Patients with Atrial FibrillationCardiac inflammation and diastolic dysfunction in hypercholesterolemic rabbits
P50
Q30276013-70C7166B-F2C6-4858-A608-B0C01AE2020CQ33762797-D9E3CDE7-DEBF-487F-85F9-2F9AD1571B44Q33790534-461DD16A-3DC1-4533-BA2A-8E628CC2C68BQ34453666-19BDF939-961F-4D90-8350-CEC9106E0C06Q34457943-A2A756E3-BA9B-49CD-B8F4-FA38D1F1A529Q34534212-A23E6EE2-08A1-4D6B-B4C3-4F459BA47BA3Q35100135-A9A89E19-A09E-4036-A008-C240256E1B13Q35735988-01591694-2E55-4B76-B4B1-45E5F0EDB7BEQ36242530-50EAE17D-1E37-4998-A7DF-7EE4EB8B35D8Q36398736-F2B76F4C-F6BE-4589-AD89-67562CCEB28FQ36851336-C7037B3B-56B0-43D3-821A-CFB05EEBA919Q36919145-E81C3510-CDD7-4C76-A461-531DD0666CC7Q37070091-1C21A029-6C89-487B-9D3F-2C25BAB91348Q38861666-FCC1B15A-A05C-4B0E-80AB-1BB404148A1FQ39177005-26A1CE3A-8375-40D0-925B-93F31C426278Q40549451-B38EE463-4281-4E04-87ED-0E2176633172Q40573539-433820AE-0305-4D59-95B2-27F8551BF9ACQ43936573-0A672BEE-C810-4212-94A6-77B2C5D52BD9Q44762986-130098BE-0353-419C-B604-F82A01604CECQ47121697-4A66F711-59DC-42D4-B352-84247C299BEEQ47750262-8FDD2F5B-5FEE-4DD4-8264-8A858C5C39EDQ50984731-6C3B911B-F910-4580-B1B6-0017CA2BC5E8Q51167013-025CE951-61C2-4BEE-830B-5BD097D9AC6FQ51372044-B1AB659A-C7D4-4A25-879B-682C7CA8395CQ52590498-27DCD136-A2AD-4937-8477-5B8BB84E17B4Q60514264-67FD7985-B91A-4953-952A-2F0038D600CDQ91379256-8159E959-A77F-4F90-B837-57925359357DQ91407753-D8638284-27A6-4B4B-9A0C-F6C786DE4CCAQ92498681-6DA3295F-0BBD-4CAD-B369-B0C00E400EE3
P50
description
Canadees cardioloog
@nl
Canadian cardiologist
@en
cardiĆ³logu canadianu
@ast
kanadischer Kardiologe
@de
name
Jean-Claude Tardif
@ast
Jean-Claude Tardif
@ca
Jean-Claude Tardif
@en
Jean-Claude Tardif
@es
Jean-Claude Tardif
@fr
Jean-Claude Tardif
@ga
Jean-Claude Tardif
@nl
Jean-Claude Tardif
@sl
Jean-Claude Tardif
@sq
type
label
Jean-Claude Tardif
@ast
Jean-Claude Tardif
@ca
Jean-Claude Tardif
@en
Jean-Claude Tardif
@es
Jean-Claude Tardif
@fr
Jean-Claude Tardif
@ga
Jean-Claude Tardif
@nl
Jean-Claude Tardif
@sl
Jean-Claude Tardif
@sq
prefLabel
Jean-Claude Tardif
@ast
Jean-Claude Tardif
@ca
Jean-Claude Tardif
@en
Jean-Claude Tardif
@es
Jean-Claude Tardif
@fr
Jean-Claude Tardif
@ga
Jean-Claude Tardif
@nl
Jean-Claude Tardif
@sl
Jean-Claude Tardif
@sq
P1006
P1015
P214
P244
P268
P269
P1006
P1015
P106
P1153
35399980400
P1207
n2011111175
P1280
P166
P1670
P1695
P2038
Jean-Claude_Tardif